Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma

被引：42

作者：

Robert, C. ^{[1
]}

Karaszewska, B. ^{[2
]}

Schachter, J. ^{[3
]}

Rutkowski, P. ^{[4
,5
]}

Mackiewicz, A. ^{[6
]}

Stroyakovskiy, D. ^{[7
]}

Lichinitser, M. ^{[8
]}

Dummer, R. ^{[9
]}

Grange, F. ^{[10
]}

Mortier, L. ^{[11
]}

Chiarion-Sileni, V. ^{[12
]}

Drucis, K. ^{[13
]}

Krajsova, I. ^{[14
]}

Hauschild, A. ^{[15
]}

Mookerjee, B. ^{[16
]}

Legos, J. ^{[16
]}

Schadendorf, D. ^{[17
]}

机构：

[1] Gustave Roussy, CH-8091 Villejuif Paris, France

[2] Przychodnia Lekarska Komed, Konin, Poland

[3] Chaim Sheba Med Ctr, Ramat Gan, Israel

[4] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[5] Inst Oncol, Warsaw, Poland

[6] Poznan Univ Med Sci, Poznan, Poland

[7] Moscow City Oncol Hosp 62, Moscow, Russia

[8] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[9] Univ Zurich Hosp, Zurich, Switzerland

[10] Ctr Hosp Univ Robert Debre, Reims, France

[11] Univ Lille 2, CHRU Lille, Lille, France

[12] Veneto Oncol Inst, Padua, Italy

[13] Med Univ, Swissmed Ctr Zdrowia SA, Gdansk, Poland

[14] VFN 1LF UK Praha, Prague, Czech Republic

[15] Univ Hosp Schleswig Holstein, Kiel, Germany

[16] GlaxoSmithKline, Collegeville, PA USA

[17] Univ Hosp Essen, Essen, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31820-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3301

引用

页码：S663 / S664

页数：3